Beginning with in vitro testing against the HER2+/CD276+ JIMT-1 (JIMT) and the HER2−/CD276+ DU4475 breast cancer cell lines (Figure 5A), we found that both ADCs exhibited potent activity against the double-positive cells (Figure 5B). Here, ERBB2 is linked to breast carcinoma.